AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- An investigational vaccine designed to prevent serious respiratory syncytial virus infection in infants by immunizing their mothers during pregnancy has passed its first clinical safety hurdle.
The Wyeth-Lederle respiratory syncytial virus (RSV) purified fusion protein-2 vaccine was safe and immunogenic in women who received it at 30-34 weeks' gestation in an exploratory 35-subject, randomized, placebo-controlled, double-blind trial. Their babies were born healthy and experienced no vaccine-related adverse events during 1 year of follow-up, Dr. Flor M. Munoz reported at the annual meeting of the Infectious Diseases Society of America.
Serum concentrations of IgG enzyme-linked immunosorbent assay (ELISA) antibody to RSV were fourfold higher when measured at birth, 2 months, and 6 months of age in the 20 babies whose mothers received the purified fusion protein vaccine, compared with the ...
Source: HighBeam Research, Maternal vaccine for infant RSV clears hurdle. (Babies Born Healthy).